Acute Coronary Syndromes
From the Journals
Icosapent ethyl’s CV mortality benefit magnified in patients with prior MI
On top of statin therapy, icosapent ethyl provides mortality reductions in patients with prior MI.
From the Journals
Study points to causal role for Lp(a) in atrial fibrillation
The relation is relatively modest but strongly argues for increased testing of Lp(a) and adding atrial fibrillation as a secondary outcome to...
Latest News
Real-world data suggest coprescribing PDE5 inhibitors and nitrates may be safe
There is a scarcity of real-world data showing that using the two types of drugs together increase cardiovascular risks, according to researchers...
From the Journals
Bariatric surgery cuts cardiovascular events, even in seniors
In persons with obesity, even those aged 65-75 years of age, bariatric surgery can reduce long-term cardiovascular events, such as heart failure,...
From the Journals
Aspirin exposure fails to reduce cardiovascular event risk
Post hoc analysis showed no additional benefit from aspirin in reducing cardiovascular risk for hypertension patients with controlled systolic...
Conference Coverage
Combo of SGLT2 inhibitor + GLP-1 RA boosts diabetes survival
Survival of patients with type 2 diabetes and CVD rose by 80% when they received both an SGLT2 inhibitor and GLP-1 RA, compared with either class...
Conference Coverage
Early PCSK9 inhibition in AMI yields plaque regression
‘Go early and go low’ is an expert’s response to the imaging results from PACMAN-AMI showing plaque reduction after AMI patients received...
Conference Coverage
APOLLO: SLN360 clears first major hurdle, hammering Lp(a)
The results add to growing enthusiasm for achieving the ‘holy grail’ of a lipoprotein(a)-specific lowering agent, but whether it will reduce...
Conference Coverage
Diltiazem fails to improve vasomotor dysfunction, angina in ANOCA: EDIT-CMD
In patients with angina and no coronary artery disease, 6 weeks of diltiazem did not improve most coronary function test results or angina...
Conference Coverage
FAME 3 subanalysis adds twist to negative primary results
A quality of life subanalysis suggests PCI with fractional flow reserve might be preferred over CABG by at least some patients.
Conference Coverage
SCORED: Sotagliflozin shows robust MACE benefit
Trial results in patients with diabetes, CKD, and high CVD risk showed robust benefits across MACE outcomes, distinguishing sotagliflozin from the...